| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease (NCT06544616) | Janssen Pharmaceutica N.V., Belgium | 2024-07-22 |
| A Study of Milvexian in Healthy Adult Females (NCT05706753) | Janssen Pharmaceutica N.V., Belgium | 2023-01-25 |
| A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment (NCT05550519) | Janssen Pharmaceutica N.V., Belgium | 2022-10-31 |
| A Study of Ponesimod in Healthy Adult Participants (NCT05552196) | Janssen Pharmaceutica N.V., Belgium | 2022-10-18 |
| A Study of JNJ-55308942 in the Treatment of Bipolar Depression (NCT05328297) | Janssen Pharmaceutica N.V., Belgium | 2022-06-03 |
| A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT05160584) | Janssen Pharmaceutica N.V., Belgium | 2021-11-18 |
| A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (NCT05049798) | Janssen Pharmaceutica N.V., Belgium | 2021-08-25 |
| A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants (NCT04388501) | Janssen Pharmaceutica N.V., Belgium | 2021-06-07 |
| A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer (NCT04557059) | Janssen Pharmaceutica N.V., Belgium | 2020-11-12 |
| A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants (NCT04426357) | Janssen Pharmaceutica N.V., Belgium | 2020-07-03 |
| A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 (NCT04380961) | Janssen Pharmaceutica N.V., Belgium | 2020-04-24 |
| A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents (NCT04236453) | Janssen Pharmaceutica N.V., Belgium | 2020-01-23 |
| Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets (NCT04006704) | Janssen Pharmaceutica N.V., Belgium | 2019-10-10 |
| A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (NCT03796858) | Janssen Pharmaceutica N.V., Belgium | 2019-03-22 |
| A Study of Ponesimod in Healthy Adult Participants Receiving Propranolol at Steady State (NCT03882255) | Janssen Pharmaceutica N.V., Belgium | 2019-03-20 |